Trials / Not Yet Recruiting
Not Yet RecruitingNCT05230771
Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer
Clinical Outcome of Palliative Surgery After Translational Therapy Versus Maintenance Chemotherapy for Metastatic Gastric Cancer: a Single Center Randomized Controlled Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This single-center, prospective study was conducted to investigate the efficacy and safety of palliative surgery after translational therapy in the treatment of metastatic gastric cancer. The primary endpoint was 2-year overall survival (OS) rate. Secondary endpoints were median OS, progression-free survival (PFS), 1-year OS, adverse events (AE), severe AE, the quality of life (QOL) and treatment cost.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Palliative surgery after translational therapy | A total, distal, or proximal gastrectomy with D1 lymph node dissection was done depending on tumour after translational therapy . location. |
| DRUG | Chemotheraoy along | Patients receive only the prescribed chemotherapy. |
Timeline
- Start date
- 2022-04-01
- Primary completion
- 2024-03-01
- Completion
- 2027-03-01
- First posted
- 2022-02-09
- Last updated
- 2022-04-01
Source: ClinicalTrials.gov record NCT05230771. Inclusion in this directory is not an endorsement.